What do systematic reviews say?

Antimicrobial vs placebo/no treatment

• Antimicrobial drugs for treating cholera 2014 · Cochrane Headline outcomes only
  no estimate extracted
  19 studies · 1013 participants
  Moderate

Antimicrobial vs placebo/no treatment

• Antimicrobial drugs for treating cholera 2014 · Cochrane Headline outcomes only
  no estimate extracted
  18 studies · 1042 participants
  Moderate

Antimicrobial vs placebo/no treatment

• Antimicrobial drugs for treating cholera 2014 · Cochrane Headline outcomes only
  no estimate extracted
  11 studies · 1201 participants
  Moderate

Antimicrobial vs placebo/no treatment

• Antimicrobial drugs for treating cholera 2014 · Cochrane Headline outcomes only
  no estimate extracted
  12 studies · 740 participants
  Moderate

Antimicrobial vs placebo/no treatment

• Antimicrobial drugs for treating cholera 2014 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 299 participants
  GRADE not reported

SHORT vs long duration of antimicrobials

Short showed no clear difference in diarrhoea duration compared with long duration of antimicrobials (low certainty).

• Antimicrobial drugs for treating cholera 2014 · Cochrane Headline outcomes only
  MD 0.34
  7 studies · 431 participants
  Low

SHORT vs long duration of antimicrobials

• Antimicrobial drugs for treating cholera 2014 · Cochrane Headline outcomes only
  no estimate extracted
  8 studies · 496 participants
  Low

SHORT vs long duration of antimicrobials

Short may leads to higher bacteriological failure compared with long duration of antimicrobials (low certainty).

• Antimicrobial drugs for treating cholera 2014 · Cochrane Headline outcomes only
  RR 1.53 [1.01, 2.32]
  9 studies · 672 participants
  Low

Rapid susceptibility methods vs standard methods versus placebo

Rapid susceptibility methods showed no clear difference in mortality compared with standard methods versus placebo (low certainty).

• Rapid versus standard antimicrobial susceptibility testing to guide treatment of bloodstream infection 2021 · Cochrane Headline outcomes only
  RR 1.1 [0.82, 1.46]
  6 studies · 1638 participants
  Low

Rapid susceptibility methods vs standard methods versus placebo

Rapid susceptibility methods showed no clear difference in mortality (subgroup genotypic) compared with standard methods versus placebo (low certainty).

• Rapid versus standard antimicrobial susceptibility testing to guide treatment of bloodstream infection 2021 · Cochrane Headline outcomes only
  RR 1.02 [0.69, 1.49]
  4 studies · 1074 participants
  Low

Rapid susceptibility methods vs standard methods versus placebo

Rapid susceptibility methods showed no clear difference in mortality (subgroup phenotypic) compared with standard methods versus placebo (low certainty).

• Rapid versus standard antimicrobial susceptibility testing to guide treatment of bloodstream infection 2021 · Cochrane Headline outcomes only
  RR 1.37 [0.8, 2.35]
  2 studies · 564 participants
  Low

Rapid susceptibility methods vs standard methods versus placebo

Rapid susceptibility methods showed no clear difference in mortality (with stewardship) compared with standard methods versus placebo (low certainty).

• Rapid versus standard antimicrobial susceptibility testing to guide treatment of bloodstream infection 2021 · Cochrane Headline outcomes only
  RR 1.17 [0.81, 1.7]
  4 studies · 1404 participants
  Low

Rapid susceptibility methods vs standard methods versus placebo

Rapid susceptibility methods showed no clear difference in mortality (without stewardship) compared with standard methods versus placebo (low certainty).

• Rapid versus standard antimicrobial susceptibility testing to guide treatment of bloodstream infection 2021 · Cochrane Headline outcomes only
  RR 0.89 [0.35, 2.27]
  2 studies · 234 participants
  Low

Rapid susceptibility methods vs standard methods versus placebo

• Rapid versus standard antimicrobial susceptibility testing to guide treatment of bloodstream infection 2021 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 1165 participants
  Low

Rapid susceptibility methods vs standard methods versus placebo

• Rapid versus standard antimicrobial susceptibility testing to guide treatment of bloodstream infection 2021 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 1493 participants
  Low

Azithromycin vs erythromycin

• Antimicrobial drugs for treating cholera 2014 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 172 participants
  Moderate

Azithromycin vs erythromycin

Azithromycin showed no clear difference in bacteriological failure compared with erythromycin (low certainty).

• Antimicrobial drugs for treating cholera 2014 · Cochrane Headline outcomes only
  RR 1.56 [0.8, 3.02]
  2 studies · 179 participants
  Low

Tetracycline vs doxycycline

• Antimicrobial drugs for treating cholera 2014 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 230 participants
  Moderate

Tetracycline vs doxycycline

• Antimicrobial drugs for treating cholera 2014 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 336 participants
  Moderate

Tetracycline vs doxycycline

Tetracycline probably leads to lower bacteriological failure compared with doxycycline (moderate certainty).

• Antimicrobial drugs for treating cholera 2014 · Cochrane Headline outcomes only
  RR 0.2 [0.06, 0.68]
  2 studies · 198 participants
  Moderate